Even in HNF1B-MODY, where insulin is often the default, incretin therapy has shown promise: semaglutide has enabled insulin withdrawal, improved time-in-range, and modest weight loss, while tirzepatide has increased fasting C-peptide and dramatically reduced insulin needs [13,14]. This evidence concerns the gene HNF1B and MODY.